Needham & Company Drops Coverage of KaloBios Pharma (KBIO)
Get Alerts KBIO Hot Sheet
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Needham & Company dropped coverage of KaloBios Pharma (NASDAQ: KBIO).
Analyst Alan Carr commented, "Kalobios announced last week plans to wind down operations and liquidate company assets. Management had expressed concern at the time that it was unlikely efforts to explore strategic alternatives would result in a viable transaction prior to depletion of cash. Kalobios ended 2Q15 with $23.2M in cash and subsequently repaid in full its outstanding $6.6M secured loan obligation.
SEC filings yesterday indicate a turnover in ownership, raising more questions with respect to future direction of the company. Because the company is not a fit with our current coverage strategy, we are DROPPING COVERAGE."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primerica (PRI) Mentioned Cautiously at Bear Cave
- TScan Therapeutics, Inc (TCRX) Announces Pricing of Upsized $150 Million Public Offering
- Xcel Energy (XEL) Files Mixed Shelf
Create E-mail Alert Related Categories
Analyst Comments, Momentum Movers, Short Sales, Trader TalkRelated Entities
Needham & Company, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!